Treatment of hepatitis C in children: a systematic review.

<h4>Background</h4>Current guidelines recommend children be treated for hepatitis C virus (HCV) using the same principles applied in adults. There are however few published studies which assess the efficacy and safety of HCV therapy in children.<h4>Methodology/principal findings<...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Hu, Karen Doucette, Lisa Hartling, Lisa Tjosvold, Joan Robinson
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2010
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/75f26d3c6b66493ba419056f876441a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75f26d3c6b66493ba419056f876441a6
record_format	dspace
spelling	oai:doaj.org-article:75f26d3c6b66493ba419056f876441a62021-12-02T20:20:08ZTreatment of hepatitis C in children: a systematic review.1932-620310.1371/journal.pone.0011542https://doaj.org/article/75f26d3c6b66493ba419056f876441a62010-07-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20644626/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Current guidelines recommend children be treated for hepatitis C virus (HCV) using the same principles applied in adults. There are however few published studies which assess the efficacy and safety of HCV therapy in children.<h4>Methodology/principal findings</h4>A systematic review of the literature was completed for studies of any design that evaluated HCV therapy in children. The primary outcome was sustained virologic response (SVR), with sub-group analysis of response rates by genotype. There were 4 randomized controlled trials (RCTs) and 31 non-randomized studies, all involving interferon, pegylated interferon (PEG-IFN), or combinations of these drugs with ribavirin. The SVR rate could not be directly compared as the populations and interventions differed across studies. Genotype was not reported or differed substantially from study to study. The overall SVR rate for PEG-IFN and ribavirin ranged from 30 to 100% which is comparable to the rate in adults. Similar to adults, the SVR rates were significantly higher in children with genotype 2 or 3 compared to genotype 1. Adverse effects were primarily flu-like symptoms and neutropenia. There were insufficient data to assess the applicability of the week 12 stop rule (stopping therapy at week 12 if there is less than a 2 log drop in HCV RNA) or the efficacy of shortening therapy to 24 weeks in children with genotype 2 and 3.<h4>Conclusions/significance</h4>Current guidelines for the treatment of HCV in children are based on limited data. Further research is needed to define the optimal therapy for HCV in children.Jia HuKaren DoucetteLisa HartlingLisa TjosvoldJoan RobinsonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 5, Iss 7, p e11542 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jia Hu Karen Doucette Lisa Hartling Lisa Tjosvold Joan Robinson Treatment of hepatitis C in children: a systematic review.
description	<h4>Background</h4>Current guidelines recommend children be treated for hepatitis C virus (HCV) using the same principles applied in adults. There are however few published studies which assess the efficacy and safety of HCV therapy in children.<h4>Methodology/principal findings</h4>A systematic review of the literature was completed for studies of any design that evaluated HCV therapy in children. The primary outcome was sustained virologic response (SVR), with sub-group analysis of response rates by genotype. There were 4 randomized controlled trials (RCTs) and 31 non-randomized studies, all involving interferon, pegylated interferon (PEG-IFN), or combinations of these drugs with ribavirin. The SVR rate could not be directly compared as the populations and interventions differed across studies. Genotype was not reported or differed substantially from study to study. The overall SVR rate for PEG-IFN and ribavirin ranged from 30 to 100% which is comparable to the rate in adults. Similar to adults, the SVR rates were significantly higher in children with genotype 2 or 3 compared to genotype 1. Adverse effects were primarily flu-like symptoms and neutropenia. There were insufficient data to assess the applicability of the week 12 stop rule (stopping therapy at week 12 if there is less than a 2 log drop in HCV RNA) or the efficacy of shortening therapy to 24 weeks in children with genotype 2 and 3.<h4>Conclusions/significance</h4>Current guidelines for the treatment of HCV in children are based on limited data. Further research is needed to define the optimal therapy for HCV in children.
format	article
author	Jia Hu Karen Doucette Lisa Hartling Lisa Tjosvold Joan Robinson
author_facet	Jia Hu Karen Doucette Lisa Hartling Lisa Tjosvold Joan Robinson
author_sort	Jia Hu
title	Treatment of hepatitis C in children: a systematic review.
title_short	Treatment of hepatitis C in children: a systematic review.
title_full	Treatment of hepatitis C in children: a systematic review.
title_fullStr	Treatment of hepatitis C in children: a systematic review.
title_full_unstemmed	Treatment of hepatitis C in children: a systematic review.
title_sort	treatment of hepatitis c in children: a systematic review.
publisher	Public Library of Science (PLoS)
publishDate	2010
url	https://doaj.org/article/75f26d3c6b66493ba419056f876441a6
work_keys_str_mv	AT jiahu treatmentofhepatitiscinchildrenasystematicreview AT karendoucette treatmentofhepatitiscinchildrenasystematicreview AT lisahartling treatmentofhepatitiscinchildrenasystematicreview AT lisatjosvold treatmentofhepatitiscinchildrenasystematicreview AT joanrobinson treatmentofhepatitiscinchildrenasystematicreview
_version_	1718374170910261248

Treatment of hepatitis C in children: a systematic review.

Ejemplares similares